Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Net Income (2018 - 2025)

Historic Net Income for Q32 Bio (QTTB) over the last 8 years, with Q3 2025 value amounting to -$7.4 million.

  • Q32 Bio's Net Income rose 5800.51% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.1 million, marking a year-over-year increase of 2878.75%. This contributed to the annual value of -$46.1 million for FY2024, which is 1420.65% up from last year.
  • As of Q3 2025, Q32 Bio's Net Income stood at -$7.4 million, which was up 5800.51% from -$9.5 million recorded in Q2 2025.
  • Q32 Bio's Net Income's 5-year high stood at $92.7 million during Q1 2022, with a 5-year trough of -$34.6 million in Q4 2022.
  • In the last 5 years, Q32 Bio's Net Income had a median value of -$14.2 million in 2024 and averaged -$11.8 million.
  • In the last 5 years, Q32 Bio's Net Income soared by 873588.07% in 2022 and then crashed by 101543.57% in 2025.
  • Q32 Bio's Net Income (Quarter) stood at -$33.6 million in 2021, then dropped by 2.94% to -$34.6 million in 2022, then increased by 21.33% to -$27.2 million in 2023, then surged by 47.83% to -$14.2 million in 2024, then skyrocketed by 47.92% to -$7.4 million in 2025.
  • Its Net Income stands at -$7.4 million for Q3 2025, versus -$9.5 million for Q2 2025 and -$11.0 million for Q1 2025.